Negative in Ames, in vitro chromosome aberration (CHO) and in vivo mouse micronucleus assays
“pacritinib was not mutagenic in a bacterial mutagenicity assay (Ames test) or clastogenic in in vitro chromosomal aberration assay (Chinese hamster ovary cells) or in vivo in a micronucleus test in mice”
2-year rat and 26-week Tg(HRAS) mouse: not carcinogenic
“Pacritinib was not carcinogenic in either a 2-year rat study or during a 26-week hemizygous Tg(HRAS) transgenic mouse study, demonstrating low carcinogenic potential secondary to inhibition of JAK2/FLT3 activity.”
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
Mouse EFD: post-implantation loss, lower fetal weight and cleft palate at maternally toxic high dose
“The NOAEL for embryo-fetal development was also considered the MD based on higher post-implantation loss, lower mean fetal body weights, and altered external fetal morphology (cleft palate) observed in the presence of maternal toxicity at the HD.”
“Pacritinib inhibited human ether-à-go-go-related gene (hERG) potassium channel with a mean IC50 of 3μM, substantially higher than free plasma concentrations at clinical exposure”
“pacritinib was not mutagenic in a bacterial mutagenicity assay (Ames test) or clastogenic in in vitro chromosomal aberration assay (Chinese hamster ovary cells) or in vivo in a micronucleus test in mice”
“pacritinib was not mutagenic in a bacterial mutagenicity assay (Ames test) or clastogenic in in vitro chromosomal aberration assay (Chinese hamster ovary cells) or in vivo in a micronucleus test in mice”
“pacritinib was not mutagenic in a bacterial mutagenicity assay (Ames test) or clastogenic in in vitro chromosomal aberration assay (Chinese hamster ovary cells) or in vivo in a micronucleus test in mice”
“Pacritinib was not carcinogenic in either a 2-year rat study or during a 26-week hemizygous Tg(HRAS) transgenic mouse study, demonstrating low carcinogenic potential secondary to inhibition of JAK2/FLT3 activity.”
2-year rat and 26-week Tg(HRAS) mouse studies completed before the marketing application
“Pacritinib was not carcinogenic in either a 2-year rat study or during a 26-week hemizygous Tg(HRAS) transgenic mouse study, demonstrating low carcinogenic potential secondary to inhibition of JAK2/FLT3 activity.”
“Pacritinib inhibited human ether-à-go-go-related gene (hERG) potassium channel with a mean IC50 of 3μM, substantially higher than free plasma concentrations at clinical exposure (human maximum concentration [Cmax] at 200 mg twice daily [BID], free fraction 240nM).”
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative